Finding new treatments for T-Cell Acute Lymphoblastic Leukemia
Official title: Discovery of MAP2K7 Inhibitors Through DNA-Encoded Chemical Screens to Treat T-Cell Acute Lymphoblastic Leukemia
Funded at Baylor College of Medicine · NIH-10947327 · Data updated 2026-11-12
This study is looking for new treatments that can help kids and young adults with T-Cell Acute Lymphoblastic Leukemia by targeting a specific protein that makes some leukemia cells resistant to current therapies, aiming to improve their chances of recovery.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $412,685 |
| NIH project number | 1R21CA286412-01A1 |
| Project ID | NIH-10947327 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children and young adults diagnosed with T-Cell Acute Lymphoblastic Leukemia, especially those who have experienced treatment failure or relapse.
✕Less likely to help
Patients with other types of leukemia or those who are not diagnosed with T-Cell Acute Lymphoblastic Leukemia may not benefit from this research.
What this research studies
This research focuses on developing new inhibitors for MAP2K7, a protein that plays a role in T-Cell Acute Lymphoblastic Leukemia (T-ALL). The study aims to identify effective therapies that can target drug-resistant leukemia cells, which are responsible for relapses in patients. By using advanced chemical screening techniques, researchers hope to discover compounds that can specifically inhibit MAP2K7 and improve treatment outcomes for patients with T-ALL. This approach is particularly important for children and young adults who are at a higher risk of treatment failure.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for T-ALL, potentially reducing relapse rates and improving survival outcomes for patients.
How similar studies have gone: While targeting MAP2K7 is a novel approach, previous research has shown promise in targeting similar pathways in leukemia treatment, indicating potential for success.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Lacorazza, Daniel — Baylor College of Medicine
- Study coordinator: Lacorazza, Daniel
Related research
Other NIH-funded projects on the same topics.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
-
Genomics of childhood ALL across diverse populations
A large international study will look at why children everywhere get acute lymphoblastic leukemia and how genetics may influence risk.
-
Combinatorial targeting for high-risk B-cell ALL treatment
A research effort at West Virginia University is exploring a combination therapy for adult B-cell acute lymphoblastic leukemia using targeted gene silencing and a small-molecule compound to improve treatment in patients.
-
Understanding why Latino children have a higher risk of childhood ALL
This project looks at why Latino children are more likely to develop acute lymphoblastic leukemia and whether genetic ancestry plays a role, with the goal of improving prevention and outcomes.
-
Targeting obesity to improve survival for children with ALL
A new approach explores whether reducing obesity-related factors can make chemotherapy work better for kids with acute lymphoblastic leukemia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.